New pill could ease severe depression
NCT ID NCT06259526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether a new drug called JS1-1-01 can safely reduce symptoms in 267 adults with moderate to severe depression. Participants took either the drug or a placebo for 8 weeks. Researchers measured changes in depression scores to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS1-1-01 pills
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe depression.
What could go wrong
This is an early-phase trial with only 267 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Capital Medical University Affiliated Anding Hospital
Beijing, Beijing Municipality, China
-
Chongqing 11th People's Hospital
Chongqing, Chongqing Municipality, China
-
Chongqing Mental Health Center
Chongqing, Chongqing Municipality, China
-
Daqing Third Hospital
Daqing, Heilongjiang, China
-
Hebei Provincial Mental Health Center
Baoding, Hebei, China
-
Huzhou Third People's Hospital
Huzhou, Zhejiang, China
-
Jiangxi Provincial Psychiatric Hospital
Nanchang, Jiangxi, China
-
Jilin Provincial Neuropsychiatric Hospital
Siping, Jilin, China
-
Peking University Sixth Hospital
Beijing, Beijing Municipality, China
-
Shandong Provincial Mental Health Center
Jinan, Shandong, China
-
The Affiliated Brain Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
-
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
Tianjin Anding Hospital
Tianjin, Tianjin Municipality, China
-
Wuxi Mental Health Center
Wuxi, Jiangsu, China
-
Zhenjiang Mental Health Center
Zhenjiang, Jiangsu, China
-
Ürümqi Fourth People's Hospital
Ürümqi, Xinjiang, China